You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 12, 2025

CLINICAL TRIALS PROFILE FOR OMECAMTIV MECARBIL


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Omecamtiv mecarbil

Trial IDTitleStatusSponsorPhaseSummary
NCT00682565 ↗ PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina Completed Cytokinetics Phase 2 This study investigates whether symptom-limited exercise capacity in ischemic cardiomyopathy patients with angina is deleteriously affected by treatment with CK-1827452.
NCT01077167 ↗ Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients Withdrawn Amgen Phase 2 The purpose of this trial is to obtain a pharmacokinetic profile (i.e. amount of drug in the blood over time) of Omecamtiv mecarbil in patients with stable heart failure.
NCT01077167 ↗ Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients Withdrawn Cytokinetics Phase 2 The purpose of this trial is to obtain a pharmacokinetic profile (i.e. amount of drug in the blood over time) of Omecamtiv mecarbil in patients with stable heart failure.
NCT01300013 ↗ Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF) Completed Cytokinetics Phase 2 The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure. This is a multicenter, randomized, double-blind, placebo-controlled study with 3 dose cohorts enrolled sequentially in order of ascending dose strength of omecamtiv mecarbil. In each cohort, subjects are randomized 1:1 to omecamtiv mecarbil or placebo.
>Trial ID>Title>Status>Phase>Summary
Showing 1 to 4 of 4 entries

Clinical Trial Conditions for Omecamtiv mecarbil

Condition Name

621100123456Heart FailureHeart Failure With Reduced Ejection FractionQT Intervals ChangesEchocardiogram[disabled in preview]
Condition Name
Intervention Trials
Heart Failure 6
Heart Failure With Reduced Ejection Fraction 2
QT Intervals Changes 1
Echocardiogram 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

102210-101234567891011Heart FailureVentricular Dysfunction, LeftSystolic MurmursIschemia[disabled in preview]
Condition MeSH
Intervention Trials
Heart Failure 10
Ventricular Dysfunction, Left 2
Systolic Murmurs 2
Ischemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Omecamtiv mecarbil

Trials by Country

+
Trials by Country
Location Trials
United States 113
Japan 46
Canada 21
China 17
Spain 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State
Location Trials
Connecticut 4
California 4
Texas 4
South Carolina 4
Oklahoma 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Omecamtiv mecarbil

Clinical Trial Phase

27.3%45.5%27.3%0-0.500.511.522.533.544.555.5Phase 3Phase 2Phase 1[disabled in preview]
Clinical Trial Phase
Clinical Trial Phase Trials
Phase 3 3
Phase 2 5
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

72.7%18.2%9.1%0012345678CompletedWithdrawnActive, not recruiting[disabled in preview]
Clinical Trial Status
Clinical Trial Phase Trials
Completed 8
Withdrawn 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Omecamtiv mecarbil

Sponsor Name

trials0246810121416CytokineticsAmgenServier[disabled in preview]
Sponsor Name
Sponsor Trials
Cytokinetics 15
Amgen 9
Servier 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

100.0%00510152025Industry[disabled in preview]
Sponsor Type
Sponsor Trials
Industry 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.